David Fedida is a Professor and an Associate Head in the Department of Anesthesiology, Pharmacology and Therapeutics at the University of British Columbia. David Fedida obtained his B.S. and Ph.D. degrees at the University of Leeds in England in fundamental cardiac electrophysiology and his Medical degree from Oxford University. After two years spent in surgical and medical residencies, he spent postdoctoral periods at Oxford with Denis Noble, Wayne Giles in Calgary, and Arthur Brown at Baylor College of Medicine in Texas where he first identified the potassium ion channel, Kv1.5, as the molecular basis of the delayed rectifier, IKur, in human atrium. He returned to Canada in 2001 and is presently a Career Investigator of the Heart and Stroke Foundation of BC and Yukon, at UBC, where he leads a research group investigating atrial potassium channels and the remodeling of ion channels in disease. This work involves understanding cardiac electrical activity in health and disease. David Fedida has consulted for companies like Roche and Xenon Pharma, and with Cardiome Pharma Corp has been actively involved in the discovery and development of Vernakalant for the past eight years as a new treatment for the acute conversion of atrial fibrillation to sinus rhythm.
Biography Updated on 31 January 2008